Skip to main content
Top
Published in: Supportive Care in Cancer 12/2017

01-12-2017 | Commentary

Evidence of depression-associated circadian rhythm disruption and regret in prostate cancer patients after surgery

Authors: Joanne Christie, Christopher F Sharpley, Vicki Bitsika, David Christie

Published in: Supportive Care in Cancer | Issue 12/2017

Login to get access

Abstract

Purpose

The purpose of this study is to investigate the association between prostate cancer (PCa) patients’ regret that their surgery harmed them, and their scores on the two key symptoms of major depressive disorder (depressed mood, anhedonia) and a symptom of melancholic depression (disruption to circadian rhythm).

Methods

Forty PCa patients who had received surgery for their PCa completed a postal survey including background information, regret about surgery that ‘did them a lot of harm’ and three items drawn from the Zung Self-Rating Depression Scale measuring depressed mood, anhedonia and circadian rhythm disruption.

Results

There were significant correlations between all three symptoms of depression (depressed mood, anhedonia, disruption to circadian rhythm) and between patients’ regret that surgery did them a lot of harm and their circadian rhythm disruption, but not between depressed mood or anhedonia and regret about surgery doing harm.

Conclusions

These findings suggest that PCa patients’ post-surgery regrets about major harm may lead to a significant disruption in a central physiological function and raise the need to consider this side effect of surgery when planning supportive services for these men.
Literature
1.
go back to reference Shakespeare T, Chin S, Manuel L, Wen S, Hoffman M, Wilcox S, Aherne N (2017) Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy. Journal of Medical Imaging and Radiation Oncology 61:141–145CrossRefPubMed Shakespeare T, Chin S, Manuel L, Wen S, Hoffman M, Wilcox S, Aherne N (2017) Long-term decision regret after post-prostatectomy image-guided intensity-modulated radiotherapy. Journal of Medical Imaging and Radiation Oncology 61:141–145CrossRefPubMed
2.
go back to reference APA (2013) Diagnostic and statistical manual of mental disorders-5. American Psychiatric Association, Washington APA (2013) Diagnostic and statistical manual of mental disorders-5. American Psychiatric Association, Washington
5.
go back to reference Sharpley C, Bitsika V, Christie D (2012) The role of melancholia in prostate cancer patients’ depression. BMC Psychiatry 12:201CrossRef Sharpley C, Bitsika V, Christie D (2012) The role of melancholia in prostate cancer patients’ depression. BMC Psychiatry 12:201CrossRef
7.
go back to reference Levitan R (2007) The chronobiology and neurobiology of winter seasonal affective disorder. Dialogues Clin Neurosci 9:315–324PubMedPubMedCentral Levitan R (2007) The chronobiology and neurobiology of winter seasonal affective disorder. Dialogues Clin Neurosci 9:315–324PubMedPubMedCentral
8.
go back to reference Brehaut J, O’Connon A, Wood T, Hack T, Siminoff L, Gordon E, Feldman-Stewart D (2003) Validation of a decision regret scale. Med Decis Mak 23:281–292CrossRef Brehaut J, O’Connon A, Wood T, Hack T, Siminoff L, Gordon E, Feldman-Stewart D (2003) Validation of a decision regret scale. Med Decis Mak 23:281–292CrossRef
Metadata
Title
Evidence of depression-associated circadian rhythm disruption and regret in prostate cancer patients after surgery
Authors
Joanne Christie
Christopher F Sharpley
Vicki Bitsika
David Christie
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 12/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3913-3

Other articles of this Issue 12/2017

Supportive Care in Cancer 12/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine